research Tata Laksana Hipoglikemia pada Pasien Diabetes
Hypoglycemia in diabetes needs quick treatment to prevent serious health issues.
Search
for
Sort by
Research
780-810 / 1000+ results research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
research BC05 Technological and clinical demonstration of a skin ageing analysis prototype
The prototype for analyzing skin aging works technically and clinically.
research CHARACTERISTICS OF IBA-1-IMMUNOPOSITIVE CELLS IN SKIN WOUNDS HEALING
Macrophages play a crucial role in skin wound healing, with their numbers and sizes changing over time.
research Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
Ruxolitinib effectively and safely regrows hair in alopecia patients.
research SnapshotDx Quiz: September 2018
Tofacitinib may help regrow hair in alopecia areata patients.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
research B-219 Apoptotic effect and cell cycle arrest by Juniperus communis extract on oral cancer
Juniperus communis extract enhances the effectiveness of oral cancer treatment when combined with chemotherapy.
research Touch
research 455 Beyond Immunity: TEC and JAK3 Kinase Activation in Melanocytes Drives Inflammation in Vitiligo
TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.
research Immunohistochemical demonstration of keratins in the epidermal layers of the Malayan pangolin (Manis javanica), with remarks on the evolution of the integumental scale armour
Keratins in Malayan pangolins vary by region, suggesting scales evolved from the tail towards the head.
research Exploring the Use of Topical Tofacitinib in Pediatric Alopecia Totalis
Topical tofacitinib may help regrow hair in children with alopecia totalis.
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
research POTENSI DAUN WARU DAN KULIT APEL SEBAGAI BAHAN AKTIF HAIR TONIC UNTUK MENGATASI RAMBUT RONTOK
Hibiscus leaves and apple skin could be effective in hair tonics to prevent hair loss.
research Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study
Baricitinib is effective for severe alopecia areata but has some side effects.
research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research Ultrasound-activated piezoelectric hydrogel scaffold for synergistic immunomodulation and angiogenesis in accelerated wound healing
The new hydrogel speeds up wound healing by reducing inflammation and promoting tissue growth.
research Case Report: Multimodal contact immunotherapy in alopecia areata: long-term clinical experience in the JAK inhibitor era
Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.
research 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research LAMELLAR ICHTHYOSIS: ONE CASE REPORT
Treatment with moisturizers improved the skin condition of a girl with a rare genetic skin disorder.
research FORMULATION AND EVALUATION OF PHYTO-HYDROGEL CONTAINING AZADIRACHTA INDICA AND TRIDAX PROCUMBENS FOR THE TREATMENT OF SEBORRHEIC DERMATITIS
The hydrogel with neem and tridax extracts effectively treats seborrheic dermatitis.
research Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
research Intravital imaging of host–parasite interactions in skin and adipose tissues
Intravital microscopy helps us see how parasites interact with skin and fat in living animals.
research Safety and efficacy of tofacitinib in 97 alopecia areata patients
Tofacitinib is an effective and safe treatment for alopecia areata.
research Nevus comedonicus in a Malay man: A case report and review of literature
A 25-year-old Malay fireman had skin bumps on his neck that were removed successfully after other treatments failed.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.